February 12, 2020 8:21am

Cell and gene therapy pricing sustainability is more of my question as Q4 and FY19 earnings are about to be announced

Pre-open indications:  4 SELLs

News: Adverum Biotechnologies (ADVM) priced its 9.5 M share offering at $13.75 per share with the usual 30-day option to purchase up to an additional 1.425 K shares

Who is defining the metrics for individual investors? Spare the SELL call, underfund the portfolio – SUBSCRIBE!


Dow future are UP +0.41% (+121 points), S&P futures are UP +0.34% (+11 points) and NASDAQ futures are UP +0.43% (+41 points)


U.S. stock index futures are on the rise on Wednesday morning;

European markets traded higher after China recorded its lowest number of new coronavirus cases since January as the pan-European Stoxx 600 added more than 0.4% to notch a fresh record high;

Asian Pacific shares traded mostly higher as investors were hopeful the number of new cases is slowing;


Data Docket: Weekly mortgage applications are due out at 7 a.m. ET, while January’s federal budget figures will be released at 2 p.m. ET on Wednesday.



The death toll from the coronavirus epidemic continues to climb, although Chinese authorities said that the rate of infection was slowing.

Back to the title, a large share of export activity is being hindered by the outbreak of the virus, especially goods production, which would be postponed rather than cancelled.

Bottom line, some markets are underestimating or outright ignoring the threat and spread of the coronavirus.


Selling into strength and preparing a cash hoard is best served – green and available!


Tuesday night’s post’s title: “fear of coronavirus or a beer in this market climate? Athazagoraphobia is the fear of being ignored while Cenosillicaphobia is the fear of an empty glass. This market is “assuming” no impact from the coronavirus>

·         The NASDAQ closed UP +10.55 points (+0.11%);

·         The IBB closed down -0.06% and XBI closed down -0.11%;

·         The close was positive with an A/D line of 22/12, 1 flat of 35 covered;

·         The range of the 22-upside was +0.15% (STML) to +19.13% (ADVM) while the 12-downside ranged from -0.66% (BLUE) to -10.48% (BLCM after a reverse split); 

·         6 out of the 22-upside had higher than the 3-month average volume;

·         1 out of the 12-downside had higher than the 3-month average volume;



February registered 2 negative and 5 positive closes – so far.

January registered 9 negative and 10 positive closes and 2 holidays.


·         December register 11 negative and 10 positive closes

·         November registered 1 holiday, 12 positive and 8 negative close;

·         October registered 10 positive, 1 neutral and 14 negative closes;


Companies in my headlights – It’s your decision; I provide an idea and context:

Pre-open indications:  SELL into strength - Adverum Biotechnologies (ADVM) closed up +$2.30 to $14.35 and is up +$0.65 or +4.49% even after pricing its offering at $13.75. Maintaining SELL on – CRISPR Therapeutics (CRSP), and Intellia Therapeutics (NTLA) as Editas Medicine got whacked (-$0.92 to $26.99). ReNeuron (RENE.L) is back on the roller-coaster with a pre-market US decline of -$1.00.



Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.